The NewCo boom signals China’s galloping speed of innovation

If anyone still doubts the competitiveness of China biotechs in innovation and dealmaking, the boom of companies founded on the so-called NewCo Model should settle that question.

The significance is not only for the pace of new company creation but for the assets on which they are based, touching on the hottest areas of innovation, such as immune cell reset and next-generation obesity therapies, where biotechs and pharmas are racing to be best if not first. ...